---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-038522"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:08:02.906554+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KalVista prices $160.1M public offering of common stock and pre-funded warrants

## Summary
- Offering includes 7,016,312 shares at $15.25 and pre-funded warrants for 3,483,688 shares; gross proceeds $160.1M.
- Net proceeds estimated at ~$150.1M to fund sebetralstat development and oral Factor XIIa program.
- Cash, cash equivalents and marketable securities approximately $76M as of Jan 31, 2024 (preliminary).
- Underwriters granted 30-day option to purchase up to 1,575,000 additional shares at same price.
- Closing expected Feb 20, 2024; Jefferies, Leerink, Stifel, Cantor joint book-runners.

## SEC filing metadata
- accession: 0001193125-24-038522
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/0001193125-24-038522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/d729040d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-038522
- JSON: https://secwatch.observer/filing/0001193125-24-038522.json
- Plain text: https://secwatch.observer/filing/0001193125-24-038522.txt

## Key facts
- Material Agreements
  KalVista Pharmaceuticals, Inc. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co. valued at approximately $150.1 million (effective 2024-02-14).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co.
  - Value: approximately $150.1 million
  - Effective: 2024-02-14
  source text: On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co., as the representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 7,016,312 shares of its common stock (the “Shares”) and (ii) pre-funded warrants to purchase 3,483,688 shares of the Company’s common stock in lieu of its common stock (the “Pre-Funded Warrants”) to certain investors, to the Underwriters (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/0001193125-24-038522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.